Evidence Hub

Efficacy of Mirikizumab in Patients with Prior Ustekinumab Exposure: A Case Series

T. Sawada, M. Nakamura, Takeshi Yamamura, K. Maeda, E. Ishikawa, Kentaro Murate, H. Kawashima

Inflammatory Bowel Diseases, 2025

10 participants · 10 citations

Abstract

This series evaluates mirikizumab efficacy in 10 ulcerative colitis patients previously treated with ustekinumab. Seven achieved corticosteroid-free remission, highlighting potential benefits despite limited data for such cases. No adverse events were reported, warranting further investigation.

How strong is the evidence?

Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 10 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free